Primecap Management Co. CA lowered its stake in Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) by 13.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,927,340 shares of the company's stock after selling 740,920 shares during the quarter. Primecap Management Co. CA owned approximately 2.35% of Allogene Therapeutics worth $10,495,000 as of its most recent SEC filing.
Other hedge funds also recently made changes to their positions in the company. abrdn plc bought a new position in Allogene Therapeutics in the 4th quarter valued at approximately $776,000. Barclays PLC lifted its stake in shares of Allogene Therapeutics by 101.5% in the 3rd quarter. Barclays PLC now owns 342,973 shares of the company's stock valued at $959,000 after acquiring an additional 172,745 shares during the last quarter. Zacks Investment Management acquired a new stake in shares of Allogene Therapeutics during the 3rd quarter valued at $1,446,000. Geode Capital Management LLC grew its position in Allogene Therapeutics by 14.4% during the 3rd quarter. Geode Capital Management LLC now owns 3,227,104 shares of the company's stock worth $9,037,000 after acquiring an additional 407,070 shares during the last quarter. Finally, Vontobel Holding Ltd. increased its holdings in Allogene Therapeutics by 788.4% in the 4th quarter. Vontobel Holding Ltd. now owns 195,457 shares of the company's stock worth $416,000 after purchasing an additional 173,457 shares in the last quarter. 83.63% of the stock is currently owned by institutional investors and hedge funds.
Insider Buying and Selling at Allogene Therapeutics
In related news, EVP Zachary Roberts sold 27,199 shares of the business's stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $1.78, for a total transaction of $48,414.22. Following the transaction, the executive vice president now owns 488,054 shares in the company, valued at $868,736.12. The trade was a 5.28 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Timothy L. Moore sold 14,746 shares of the stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $1.71, for a total transaction of $25,215.66. Following the transaction, the insider now directly owns 250,713 shares in the company, valued at approximately $428,719.23. This represents a 5.55 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 104,866 shares of company stock valued at $194,461. 24.30% of the stock is currently owned by company insiders.
Analyst Upgrades and Downgrades
Several analysts have recently weighed in on ALLO shares. HC Wainwright reduced their price target on Allogene Therapeutics from $9.00 to $8.00 and set a "buy" rating on the stock in a report on Wednesday, March 19th. Citizens Jmp raised shares of Allogene Therapeutics from a "market perform" rating to an "outperform" rating and set a $5.00 target price on the stock in a report on Friday, March 14th. Canaccord Genuity Group restated a "buy" rating and issued a $14.00 price target on shares of Allogene Therapeutics in a research report on Friday, March 14th. Finally, Royal Bank of Canada reiterated an "outperform" rating and set a $10.00 price target on shares of Allogene Therapeutics in a report on Friday, March 14th. One investment analyst has rated the stock with a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $9.29.
View Our Latest Analysis on ALLO
Allogene Therapeutics Price Performance
Shares of ALLO traded up $0.06 during trading hours on Monday, hitting $1.68. 2,085,672 shares of the stock were exchanged, compared to its average volume of 3,096,903. Allogene Therapeutics, Inc. has a fifty-two week low of $1.32 and a fifty-two week high of $4.63. The business has a 50-day moving average of $1.89 and a 200-day moving average of $2.28. The firm has a market capitalization of $365.01 million, a P/E ratio of -1.08 and a beta of 1.02.
Allogene Therapeutics (NASDAQ:ALLO - Get Free Report) last posted its quarterly earnings data on Thursday, March 13th. The company reported ($0.28) earnings per share for the quarter, topping the consensus estimate of ($0.34) by $0.06. As a group, analysts forecast that Allogene Therapeutics, Inc. will post -1.28 earnings per share for the current fiscal year.
About Allogene Therapeutics
(
Free Report)
Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).
Read More
Before you consider Allogene Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Allogene Therapeutics wasn't on the list.
While Allogene Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
